
Domenico Scrutinio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6479834/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions. Heart Failure Reviews, 2023, 28, 683-695.	3.9	3
2	Characteristics, Outcomes, and Long-Term Survival of Patients With Heart Failure Undergoing Inpatient Cardiac Rehabilitation. Archives of Physical Medicine and Rehabilitation, 2022, 103, 891-898.e4.	0.9	7
3	Association of improvement in functional capacity after rehabilitation with long-term survival in heart failure. International Journal of Cardiology, 2022, 352, 92-97.	1.7	4
4	Prognostic value of functional capacity after transitional rehabilitation in older patients hospitalized for heart failure. Journal of the American Geriatrics Society, 2022, 70, 1774-1784.	2.6	4
5	Old and new equations for maximal heart rate prediction in patients with heart failure and reduced ejection fraction on beta-blockers treatment: results from the MECKI score data set. European Journal of Preventive Cardiology, 2022, 29, 1680-1688.	1.8	11
6	Iron Deficiency: A New Target for Patients With Heart Failure. Frontiers in Cardiovascular Medicine, 2021, 8, 709872.	2.4	29
7	Age and comorbidities are crucial predictors of mortality in severe obstructive sleep apnoea syndrome. European Journal of Internal Medicine, 2021, 90, 71-76.	2.2	8
8	Malnutrition in patients admitted to in-hospital cardiac rehabilitation: Clinical correlates and association with mortality. Monaldi Archives for Chest Disease, 2021, , .	0.6	2
9	Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure. European Journal of Internal Medicine, 2020, 71, 23-31.	2.2	29
10	Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction. ESC Heart Failure, 2020, 7, 368-377.	3.1	23
11	Association Between Malnutrition and Outcomes in Patients With Severe Ischemic Stroke Undergoing Rehabilitation. Archives of Physical Medicine and Rehabilitation, 2020, 101, 852-860.	0.9	32
12	Machine learning to predict mortality after rehabilitation among patients with severe stroke. Scientific Reports, 2020, 10, 20127.	3.3	48
13	Role of comorbidities in heart failure prognosis Part 2: Chronic kidney disease, elevated serum uric acid. European Journal of Preventive Cardiology, 2020, 27, 35-45.	1.8	34
14	Risk scores did not reliably predict individual risk of mortality for patients with decompensated heart failure. Journal of Clinical Epidemiology, 2020, 125, 38-46.	5.0	6
15	Diffuse idiopathic skeletal hyperostosis in subjects with congestive heart failure undergoing cardiac rehabilitation: A decision tree analysis. Journal of Rehabilitation Medicine, 2020, 52, jrm00030.	1.1	3
16	Sex Differences in Long-Term Mortality and Functional Outcome After Rehabilitation in Patients With Severe Stroke. Frontiers in Neurology, 2020, 11, 84.	2.4	24
17	Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test. Journal of Cardiac Failure, 2020, 26, 932-943.	1.7	8
18	Long-term prognostic potential of microRNA-150-5p in optimally treated heart failure patients with reduced ejection fraction. A pilot study. Minerva Cardiology and Angiology, 2020, , .	0.7	1

DOMENICO SCRUTINIO

#	Article	IF	CITATIONS
19	Risk stratification in acute heart failure: We need a new agenda for clinical research. International Journal of Cardiology, 2019, 293, 179-180.	1.7	Ο
20	Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and midâ€range ejection fraction. European Journal of Heart Failure, 2019, 21, 1586-1595.	7.1	24
21	Rehabilitation Outcomes of Patients With Severe Disability Poststroke. Archives of Physical Medicine and Rehabilitation, 2019, 100, 520-529.e3.	0.9	9
22	The new frontiers of rehabilitation medicine in people with chronic disabling illnesses. European Journal of Internal Medicine, 2019, 61, 1-8.	2.2	9
23	Acutely decompensated heart failure with chronic obstructive pulmonary disease: Clinical characteristics and long-term survival. European Journal of Internal Medicine, 2019, 60, 31-38.	2.2	6
24	Modes of death and prognostic outliers in chronic heart failure. American Heart Journal, 2019, 208, 100-109.	2.7	7
25	Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years. European Journal of Heart Failure, 2019, 21, 208-217.	7.1	60
26	Response by Guida and Scrutinio to Letter Regarding Article, "Development and Validation of a Predictive Model for Functional Outcome After Stroke Rehabilitation: The Maugeri Model― Stroke, 2018, 49, e134.	2.0	0
27	Female gender and mortality risk in decompensated heart failure. European Journal of Internal Medicine, 2018, 51, 34-40.	2.2	16
28	Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a longâ€ŧerm comparison. European Journal of Heart Failure, 2018, 20, 700-710.	7.1	84
29	Measures of hospital competition and their impact on early mortality for congestive heart failure, acute myocardial infarction and cardiac surgery. International Journal for Quality in Health Care, 2018, 31, 598-605.	1.8	1
30	Right heart dysfunction. Journal of Cardiovascular Medicine, 2018, 19, 613-623.	1.5	10
31	Dose-dependent efficacy of β-blocker in patients with chronic heart failure and atrial fibrillation. International Journal of Cardiology, 2018, 273, 141-146.	1.7	13
32	Application of competing risks analysis improved prognostic assessment of patients with decompensated chronic heart failure and reduced left ventricular ejection fraction. Journal of Clinical Epidemiology, 2018, 103, 31-39.	5.0	2
33	Relationship among body mass index, NT-proBNP, and mortality inÂdecompensated chronic heart failure. Heart and Lung: Journal of Acute and Critical Care, 2017, 46, 172-177.	1.6	4
34	Circulating microRNA-150-5p as a novel biomarker for advanced heart failure: A genome-wide prospective study. Journal of Heart and Lung Transplantation, 2017, 36, 616-624.	0.6	70
35	Development and Validation of a Predictive Model for Functional Outcome After Stroke Rehabilitation. Stroke, 2017, 48, 3308-3315.	2.0	52
36	Mediterranean diet impact on cardiovascular diseases. Journal of Cardiovascular Medicine, 2017, 18, 925-935.	1.5	55

#	Article	IF	CITATIONS
37	Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Postâ€Hoc Analysis of the GISSIâ€HF (Gruppo Italiano per lo Studio della Sopravvivenza nella) Tj ETQq1	1:0778431	. ∕5∎ gBT /Ove
38	Early mortality following percutaneous coronary intervention and cardiac surgery: Correlations within providers and operators. International Journal of Cardiology, 2017, 240, 97-102.	1.7	3
39	Heart failure and anemia: Effects on prognostic variables. European Journal of Internal Medicine, 2017, 37, 56-63.	2.2	33
40	Predictors of Longâ€Term Mortality in Older Patients Hospitalized for Acutely Decompensated Heart Failure: Clinical Relevance of Natriuretic Peptides. Journal of the American Geriatrics Society, 2017, 65, 822-826.	2.6	12
41	Critical Appraisal of Multivariable Prognostic Scores in Heart Failure: Development, Validation and Clinical Utility. Advances in Experimental Medicine and Biology, 2017, 1067, 387-403.	1.6	2
42	Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: data from the <scp>MECKI</scp> Score Research Group. European Journal of Heart Failure, 2016, 18, 545-553.	7.1	64
43	Mutational Spectrum of <i>CYP24A1</i> Gene in a Cohort of Italian Patients with Idiopathic Infantile Hypercalcemia. Nephron, 2016, 133, 193-204.	1.8	23
44	Incremental utility of prognostic variables at discharge for risk prediction in hospitalized patients with acutely decompensated chronic heart failure. Heart and Lung: Journal of Acute and Critical Care, 2016, 45, 212-219.	1.6	2
45	Intra-hospital correlations among 30-day mortality rates in 18 different clinical and surgical settings. International Journal for Quality in Health Care, 2016, 28, 793-801.	1.8	7
46	Long-term prognostic implications of the ADHF/NT-proBNP risk score in patients admitted with advanced heart failure. Journal of Heart and Lung Transplantation, 2016, 35, 1264-1267.	0.6	3
47	Tricuspid Annular Plane Systolic Excursion in Acute Decompensated Heart Failure: Relevance for Risk Stratification. Canadian Journal of Cardiology, 2016, 32, 963-969.	1.7	6
48	Prognostic impact of comorbidities in hospitalized patients with acute exacerbation of chronic heart failure. European Journal of Internal Medicine, 2016, 34, 63-67.	2.2	18
49	Sex Profile and Risk Assessment With Cardiopulmonary Exercise Testing in Heart Failure: Propensity Score Matching for Sex Selection Bias. Canadian Journal of Cardiology, 2016, 32, 754-759.	1.7	19
50	The metabolic exercise test data combined with Cardiac And Kidney Indexes (MECKI) score and prognosis in heart failure. A validation study. International Journal of Cardiology, 2016, 203, 1067-1072.	1.7	36
51	Exercise Performance Is a Prognostic Indicator in Elderly Patients With Chronic Heart Failure – Application of Metabolic Exercise Cardiac Kidney Indexes Score –. Circulation Journal, 2015, 79, 2608-2615.	1.6	21
52	Renal Function and Peak Exercise Oxygen Consumption in Chronic Heart Failure With Reduced Left Ventricular Ejection Fraction. Circulation Journal, 2015, 79, 583-591.	1.6	29
53	Predicting Short-Term Mortality in Advanced Decompensated Heart Failure – Role of the Updated Acute Decompensated Heart Failure/N-Terminal Pro-B-Type Natriuretic Peptide Risk Score –. Circulation Journal, 2015, 79, 1076-1083.	1.6	15
54	Prognostic role of atrial fibrillation in patients affected by chronic heart failure. Data from the MECKI score research group. European Journal of Internal Medicine, 2015, 26, 515-520.	2.2	16

DOMENICO SCRUTINIO

#	Article	IF	CITATIONS
55	Regular Wine Consumption in Chronic Heart Failure. Circulation: Heart Failure, 2015, 8, 428-437.	3.9	26
56	Metabolic exercise data combined with cardiac and kidney indexes: MECKI score. Predictive role in cardiopulmonary exercise testing with low respiratory exchange ratio in heart failure. International Journal of Cardiology, 2015, 184, 299-301.	1.7	10
57	Functional Gain After Inpatient Stroke Rehabilitation. Stroke, 2015, 46, 2976-2980.	2.0	49
58	Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation. European Journal of Preventive Cardiology, 2015, 22, 1046-1055.	1.8	32
59	Predicting mortality in patients with acute heart failure: Role of risk scores. World Journal of Cardiology, 2015, 7, 902.	1.5	65
60	lvabradine, coronary artery disease, and heart failure: beyond rhythm control. Drug Design, Development and Therapy, 2014, 8, 689.	4.3	18
61	Combined Use of High-sensitivity C-Reactive Protein and N-Terminal Pro-B-type Natriuretic Peptide for Risk Stratification ofAVascular Surgery Patients. Annals of Vascular Surgery, 2014, 28, 1522-1529.	0.9	10
62	The ADHF/NT-proBNP risk score to predict 1-year mortality in hospitalized patients with advanced decompensated heart failure. Journal of Heart and Lung Transplantation, 2014, 33, 404-411.	0.6	21
63	Renal Dysfunction and Accuracy of N-Terminal Pro-B-Type Natriuretic Peptide in Predicting Mortality for Hospitalized Patients With Heart Failure. Circulation Journal, 2014, 78, 2439-2446.	1.6	9
64	Endothelial Function in Obese and Overweight Patients: The Role of Olive Oil, Fish and Nuts. International Journal of Diabetes and Clinical Research, 2014, 1, .	0.2	2
65	Prognostic Value of Indeterminable Anaerobic Threshold in Heart Failure. Circulation: Heart Failure, 2013, 6, 977-987.	3.9	60
66	Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: A multiparametric approach to heart failure prognosis. International Journal of Cardiology, 2013, 167, 2710-2718.	1.7	183
67	Severe heart failure prognosis evaluation for transplant selection in the era of beta-blockers: Role of peak oxygen consumption. International Journal of Cardiology, 2013, 168, 5078-5081.	1.7	25
68	Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/NT-proBNP risk score. International Journal of Cardiology, 2013, 168, 2120-2126.	1.7	58
69	Association Between Conformity With Performance Measures and 1-Year Postdischarge Survival in Patients With Acute Decompensated Heart Failure. American Journal of Medical Quality, 2013, 28, 160-168.	0.5	7
70	Inpatient Cardiac Rehabilitation Soon After Hospitalization for Acute Decompensated Heart Failure. Journal of Cardiopulmonary Rehabilitation and Prevention, 2012, 32, 71-77.	2.1	23
71	Clinical utility of different estimates of renal function for predicting mortality in chronic heart failure. International Journal of Cardiology, 2012, 157, 24-30.	1.7	8
72	Ophthalmic Artery Vasodilation after Intranasal Estradiol Use in Postmenopausal Women. Journal of Atherosclerosis and Thrombosis, 2012, 19, 1061-1065.	2.0	11

DOMENICO SCRUTINIO

#	Article	IF	CITATIONS
73	Vorapaxar in the Secondary Prevention of Atherothrombotic Events. New England Journal of Medicine, 2012, 366, 1404-1413.	27.0	841
74	Aminoâ€Terminal Proâ€Bâ€Type Natriuretic Peptide for Risk Prediction in Acute Decompensated Heart Failure. Congestive Heart Failure, 2012, 18, 308-314.	2.0	2
75	Detection and prognostic impact of renal dysfunction in patients with chronic heart failure and normal serum creatinine. International Journal of Cardiology, 2011, 147, 228-233.	1.7	10
76	High-sensitivity C-reactive protein predicts cardiovascular events and myocardial damage after vascular surgery. Journal of Vascular Surgery, 2011, 54, 474-479.	1.1	8
77	The cardiorenal anaemia syndrome in systolic heart failure: prevalence, clinical correlates, and longâ€ŧerm survival. European Journal of Heart Failure, 2011, 13, 61-67.	7.1	62
78	The Potential of Lifestyle Changes for Improving the Clinical Outcome of Patients with Coronary Heart Disease: Mechanisms of Benefit and Clinical Results. Reviews on Recent Clinical Trials, 2010, 5, 1-13.	0.8	13
79	Clopidogrel idrogenosolfato versus aspirina nella riduzione degli eventi aterotrombotici nelle popolazioni a elevato rischio cardiovascolare: un'analisi italiana di costo-efficacia basata sul trial CAPRIE. Pharmacoeconomics Italian Research Articles, 2010, 12, 33-50.	0.2	3
80	Long-term secondary prevention programs after cardiac rehabilitation for the reduction of future cardiovascular events: focus on regular physical activity. Future Cardiology, 2009, 5, 297-314.	1.2	10
81	Comorbidity in patients undergoing coronary artery bypass graft surgery: impact on outcome and implications for cardiac rehabilitation. European Journal of Cardiovascular Prevention and Rehabilitation, 2008, 15, 379-385.	2.8	51
82	Global Secondary Prevention Strategies to Limit Event Recurrence After Myocardial Infarction. Archives of Internal Medicine, 2008, 168, 2194.	3.8	320
83	Permanent atrial fibrillation affects exercise capacity in chronic heart failure patients. European Heart Journal, 2008, 29, 2367-2372.	2.2	73
84	Prognostic value of formulas estimating excretory renal function in the elderly with systolic heart failure. Age and Ageing, 2008, 38, 296-301.	1.6	10
85	Short-Term Change in Distance Walked in 6 Min Is an Indicator of Outcome in Patients With Chronic Heart Failure in Clinical Practice. Journal of the American College of Cardiology, 2006, 48, 99-105.	2.8	84
86	Metabolic Treatment with <i>L</i> -Carnitine in Acute Anterior ST Segment Elevation Myocardial Infarction. Cardiology, 2006, 106, 215-223.	1.4	42
87	Cardiac Rehabilitation in the Elderly: Patient Selection and Outcomes. The American Journal of Geriatric Cardiology, 2006, 15, 22-27.	0.6	26
88	Physical activity for coronary heart disease: cardioprotective mechanisms and effects on prognosis. Monaldi Archives for Chest Disease, 2005, 64, 77-87.	0.6	15
89	Distance Walked in the 6-Minute Test Soon After Cardiac Surgery. Chest, 2004, 126, 1796-1801.	0.8	63
90	APO(a) Variants and Lipoprotein(a) in Men with or without Myocardial Infarction. Experimental and Molecular Pathology, 2002, 73, 28-34.	2.1	11

6

#	Article	IF	CITATIONS
91	Ticlopidine versus aspirin after myocardial infarction (stami) trial. Journal of the American College of Cardiology, 2001, 37, 1259-1265.	2.8	61
92	Reduced costs with bisoprolol treatment for heart failure; an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II). European Heart Journal, 2001, 22, 1021-1031.	2.2	35
93	Low-dose dobutamine responsiveness in idiopathic dilated cardiomyopathy: relation to exercise capacity and clinical outcome. European Heart Journal, 2000, 21, 927-934.	2.2	64
94	The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet, The, 1999, 353, 9-13.	13.7	4,091
95	Study on propionyl-?-carnitine in chronic heart failure. European Heart Journal, 1999, 20, 70-76.	2.2	37
96	Percent achieved of predicted peak exercise oxygen uptake and kinetics of recovery of oxygen uptake after exercise for risk stratification in chronic heart failure. International Journal of Cardiology, 1998, 64, 117-124.	1.7	30
97	Sleep suppression of ventricular arrhythmias: a predictor of beta-blocker efficacy. European Heart Journal, 1996, 17, 917-925.	2.2	12
98	Comparison of a fixed combination of nifedipine slow release and atenolol (Bay-R-1999) and nifedipine slow release alone in patients with stable angina pectoris: A multicenter, randomized, double-blind, parallel-group study. Current Therapeutic Research, 1995, 56, 1175-1184.	1.2	0
99	Transient myocardial ischemia in patients with chronic angina: relation to heart rate changes and variability in exercise threshold. International Journal of Cardiology, 1995, 49, 215-223.	1.7	3
100	Effects of l-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the l-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) trial. Journal of the American College of Cardiology, 1995, 26, 380-387.	2.8	152
101	Prediction of mortality in mild to moderately symptomatic patients with left ventricular dysfunction. European Heart Journal, 1994, 15, 1089-1095.	2.2	54
102	Efficacy and duration of action of sustained-release diltiazem in patients with chronic stable effort angina. Current Therapeutic Research, 1993, 54, 672-679.	1.2	0
103	Recombinant tissue type plasminogen activator and heparin in acute angina at rest. Current Therapeutic Research, 1993, 53, 665-676.	1.2	0
104	A Digital Network for Long-distance Echocardiographic Image and Data Transmission in Clinical Trials: The CEDIM Study Experience. Journal of the American Society of Echocardiography, 1993, 6, 583-592.	2.8	11
105	Propionil-L-carnitine: a new compound in the metabolic approach to the treatment of effort angina. International Journal of Cardiology, 1992, 34, 167-172.	1.7	22
106	Thrombolysis in unstable angina: Results of clinical studies. American Journal of Cardiology, 1991, 68, B99-B104.	1.6	8
107	Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group Circulation, 1990, 82, 17-26.	1.6	413
108	Objective evaluation of gallopamil in patients with chronic stable angina European Heart Journal, 1989, 10, 168-176.	2.2	11

#	Article	IF	CITATIONS
109	Randomized placebo-controlled comparative study of nifedipine, verapamil and isosorbide dinitrate in the treatment of angina at rest. European Heart Journal, 1986, 7, 67-76.	2.2	13
110	Ischaemia related ventricular arrhythmias in patients with variant angina pectoris. European Heart Journal, 1984, 5, 1013-1022.	2.2	9
111	Evaluation of pentisomide on stable ventricular premature beats. Comparison with placebo. European Heart Journal, 0, , .	2.2	1